The low-energy β− and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy
- 1 August 2011
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 38 (6) , 917-924
- https://doi.org/10.1016/j.nucmedbio.2011.02.007
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Target burn-up corrected specific activity of 177Lu produced via 176Lu(n, γ) 177Lu nuclear reactionsApplied Radiation and Isotopes, 2008
- Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic originEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Auger radiation targeted into DNA: a therapy perspectiveEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximabEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activitiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Production of terbium-152 by heavy ion reactions and proton induced spallationApplied Radiation and Isotopes, 2000
- Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000